Adhesive brands for wounds and abrasions are about product attributes. But Band-Aid, like Kleenex or even Xerox, has so much brand equity that for most people it pretty much has become the name for the category, which is kind of a curse.
SOURCE: Hospital Administration News – Read entire story here.
Related posts:
- Have Professional CGMs Passed Their Prime? It was only a Powerpoint slide, but it was the scariest thing I ever saw in my life. The slide showed a blood sugar trend line from a continuous glucose monitor (CGM), not very different from the ones I've seen myself time and time again from my o... ...
- Opinion | Doctors Like Me Are Falling Into This Medical Bill Trap Thank goodness for urgent care centers. Last July my daughter was still limping a week […] ...
- Psychological First Aid Kit By: Christina Koch, Intern, U.S. Department of EducationThere are many different reactions that people can have after an emergency. Sometimes these reactions can lead to distress that can get in the way of proper coping. If needed, PFA can help people cope with their reactions and recover.Tagged: Trauma | Schools | Disasters and Traumatic Events ...
- Coast Guard assists sick Vineyard man A 68-year-old man who became ill on Martha's Vineyard was flown off the island to a Boston hospital early Thursday morning by a Coast Guard air crew. The Coast Guard 1st District Command Center was notified at midnight by Martha's Vineyard Hospital that the man had internal bleeding and needed immediate transportation to a mainland medical facility, according to the Coast Guard. ...
- Peregrine Pharmaceuticals Enters Into Research Collaboration to… Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development for the treatment of lung cancer, today announced that the company has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to explore the potential of Peregrine's proprietary phosphatidylserine -targeting antibody platform. The goal of the research is to identify effective treatment combinations based on Peregrine's PS-targeting agents, including Peregrine's lead clinical agent bavituximab, with other checkpoint inhibitors or immune stimulating agents that will further guide the bavituximab clinical development program. ...
